Subscriber Only
Business
Deals
Merck Turns to Tumor-Killing Viruses to Boost Immune Cancer Drugs
- Oncolytic viruses resurge in the wake of checkpoint inhibitors
- Merck plans to pay $390 million for experimental virus therapy

Illustration: Science Photo Library